Literature DB >> 35253237

Management of oral leukoplakia by ablative fractional laser-assisted photodynamic therapy: A 3-year retrospective study of 48 patients.

Yi-Lin Yao1, Yu-Feng Wang1, Chen-Xi Li1, Lan Wu1, Guo-Yao Tang1.   

Abstract

OBJECTIVES: This study aimed to review the results of oral leucoplakia (OL) using ablative fractional laser-assisted photodynamic therapy (AFL-PDT) and to further evaluate the risk factors for recurrence and malignant transformation.
MATERIALS AND METHODS: Forty-eight patients diagnosed with OL using histopathology were enrolled in this study. All patients received one session of AFL-PDT. Therapeutic efficacy was evaluated 1 month posttreatment. Follow-up was scheduled every 3 months in the first year and every 6 months thereafter.
RESULTS: An overall positive response rate of 87.5% (42/48) was achieved, including 62.5% (30/48) complete responses and 25.0% (12/48) partial responses. During the 3-year follow-up period, the recurrence and malignant transformation rates were 37.5% (18/48) and 8.3% (4/48), respectively. Lesions on gingiva/palate seemed to be associated with recurrence (p < 0.001; odds ratio [OR]: 1.64, 95% confidence interval [CI]: 1.13-2.37). The severity of epithelial dysplasia (p = 0.02; OR: 2.93, 95% CI: 1.96-4.42) and recurrence (p = 0.016; OR: 3.14, 95% CI: 2.04-4.84) were associated with a predisposition to malignant transformation.
CONCLUSIONS: AFL-PDT is an effective management of OL, but requires close follow-up. OL lesions on the gingiva/palate are predisposed to recurrence. OLs that recur with moderate/severe epithelial dysplasia have a higher risk of transforming into oral squamous cell carcinoma.
© 2022 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.

Entities:  

Keywords:  ablative fractional laser; malignant transformation; oral leukoplakia; photodynamic therapy; recurrence

Mesh:

Substances:

Year:  2022        PMID: 35253237      PMCID: PMC9314786          DOI: 10.1002/lsm.23534

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092


INTRODUCTION

The World Health Organization (WHO) defined oral leucoplakia (OL) as “a white patch or plaque that cannot be characterised clinically or pathologically as any other disease.” The prevalence of OL is approximately 3%, , of which 10%–36% of cases occur in oral squamous cell carcinoma (OSCC). , Consequently, OL is considered one of the most common oral mucosal diseases and premalignant disorders. Treatment modalities for OL include scalpel excision, laser therapy, cryotherapy, topical application of bleomycin and vitamin A, and systemic administration of β‐carotene, lycopene, and retinoids. , Photodynamic therapy (PDT) is an attractive treatment for OL, since large or multiple lesions can be treated with low toxicity, minimal invasiveness, and high selectivity. , However, the penetration depth of photosensitizers into the lesion is a significant limitation for PDT efficacy. , Ablative fractional laser (AFL) has been proven to be effective through in vitro and in vivo studies. , AFL is also recommended by the guidelines for topical PDT for enhancing the uptake of topically applied photosensitizers and intensifying PDT response during the treatment of premalignant diseases. One case study has reported that an OL with a large area was successfully treated by AFL‐assisted PDT (AFL‐PDT) but not by PDT alone, which demonstrated the therapeutic effect of AFL in AFL‐PDT. However, the efficacy of AFL‐PDT for OL has not been summarised. In this study, we reviewed the results of OL patients who were treated with AFL‐PDT and evaluated the therapeutic effects, recurrence, malignant transformation, and associated risk factors.

MATERIALS AND METHODS

Patients

Consecutive OL patients treated at the Department of Oral Mucosal Disease, Shanghai Ninth People's Hospital, between March 2018 and August 2018 were recruited for this study. Approval was obtained from the ethics committee before initiation (2016‐115‐T64). Patients with untreated OLs were screened for inclusion. The inclusion criteria were OL as verified by the diagnostic standard and an age range of 18–75 years. The exclusion criteria were pregnancy/lactation, histopathological diagnosis of other mucosal diseases, severe malignancies, and poor general condition.

Treatment procedures

The OL lesion was prepared to facilitate the penetration of 5‐aminolevulinic acid (ALA Zhangjiang Pharmaceuticals) before the application of ALA. After local anaesthesia, the stratum corneum was carefully removed with AFL (Juehua Medical Devices Co., Ltd.). The following AFL parameters were used: a square pattern with a coverage rate of 9%, wavelength of 10.6 μm, fluence of 15 W/cm2, pulse duration of 52.5 ms, interval of 1.0 ms, and spot pitch of 0.6 mm. Vaporised crusts were cleared with saline cotton swabs and subsequently lifted. The prepared 20% ALA gel was applied to the lesion and successively covered with a piece of glutinous rice paper, plastic wrap, and gauze for saliva isolation. A high‐potency vacuum device was used for salivary suction. The illumination procedure was performed 3 h after occlusion of the ALA and involved the administration of red light (Yage LED‐IB photodynamic therapy instrument Co., Ltd.) at a wavelength of 630 nm, light dose of 180 J/cm2, and fluence rate of 100 source. Light was imaged on the lesion surface at a spot of 1‐cm diameter for 5 min. Each spot was overlapped with adjacent spots by 3 mm to cover the entire lesion. In each treatment session, the treatment area was limited to 4 cm2 or a diameter of 3 cm. Each treatment area underwent one session of AFL‐PDT treatment.

Follow‐up

Follow‐up was performed 1 month postoperatively, every 3 months in the first year, and every 6 months thereafter. The treated area was measured using a periodontal probe and was recorded using a digital camera. An experienced expert in oral mucosal disease performed the clinical examination, including treatment response, clinical recurrence, and malignant transformation. Therapeutic efficacy was evaluated in terms of the clinical treatment response at 1 month postoperatively and classified as complete response (CR, 100% reduction in lesion size), partial response (PR, more than 30% reduction in lesion size), or no response (NR, less than 30% reduction in lesion size or even worsening). Clinical recurrence was evaluated at every follow‐up, except for the first time, and described as being present or absent. A biopsy was performed once the lesion appeared nonhomogenous, which indicates a higher potential for malignant transformation. Patients completed the follow‐up and received treatment once the lesion transformed into OSCC at any time during the study.

Statistical analysis

Logistic regression was used to evaluate the odds ratios (ORs) and associations among the variables. An asymptotic 95% confidence interval (CI) for the OR was calculated. All tests were two‐sided, and p < 0.05 were considered statistically significant. All analyses were performed using SPSS version 13.0 (SPSS Inc.).

RESULTS

A total of 48 patients with OL who met the inclusion criteria and underwent AFL‐PDT were enrolled in the study. Of the 48 patients, the population consisted of 62.5% (30/48) female and 37.5% (18/48) male. The patient characteristics at baseline were as follows: average age (SD) of 60.7 (11.9) years; tobacco history (yes/no), 29.2% (14/48)/70.8% (34/48); alcohol history (yes/no), 12.5% (6/48)/87.5% (42/48). Of the lesions, 41.7% (20/48) were located on the margin surface of the tongue, followed by the cheek mucosa (37.5%, 18/48), gingiva (8.3%, 4/48), palate (6.2%, 3/48), dorsal surface of the tongue (4.2%, 2/48), and floor of the mouth (2.1%, 1/48). Mild, moderate, severe, and no dysplasia were observed in 56.3% (27/48), 31.3% (15/48), 8.3% (4/48), and 4.2% (2/48) of the overall OL patient population, respectively.

Treatment response

After one session of AFL‐PDT, 87.5% (42/48) of the OL patients achieved an overall positive response, whereas 12.5% (6/48) did not exhibit any change. Among the 42 responders, 30 and 12 showed CR (Figure 1A) and PR (Figure 1B) to AFL‐PDT, respectively.
Figure 1

Clinical pictures of different efficacies. The OL lesion (blue line) showed a complete response (CR, A) or a partial response (PR, B) to ablative fractional laser‐assisted photodynamic therapy (AFL‐PDT)

Clinical pictures of different efficacies. The OL lesion (blue line) showed a complete response (CR, A) or a partial response (PR, B) to ablative fractional laser‐assisted photodynamic therapy (AFL‐PDT)

Clinical recurrence

During the 3‐year follow‐up, 37.5% (18/48) of the OLs recurred, with an average recurrence time of 6.4 months. Recurrence was observed in 30.0% (9/30) CR lesions, 50.0% (6/12) PR lesions, and 50.0% (3/6) NR lesions. The main characteristics of the recurrence group are presented in Table 1. Univariate analyses revealed that sex, smoking, alcohol history, and epithelial dysplasia did not reach statistical significance (p > 0.05). Notably, univariable analyses and Kaplan–Meier curves for time to recurrence (Figure 2) showed that gingiva/palate was significantly associated with recurrence (p < 0.001; OR: 1.64, 95% CI: 1.13–2.37).
Table 1

Univariable analysis of risk factor for recurrence OL after AFL‐PDT treatment

CharacteristicsNon‐recurrence OLRecurrence OLUnivariable analysis
Total, n (%)30 (62.5)18 (37.5)OR (95% CI)
Sex p = 0.363
Female17 (56.7)13 (43.3)1.0 (ref)
Male13 (72.2)5 (27.8)1.99 (0.56–7.00)
Tobacco p = 0.521
Yes10 (71.4)4 (28.6)1.0 (ref)
No20 (58.8)14 (41.2)0.57 (0.15–2.20)
Alcohol p = 0.179
Yes2 (33.3)4 (66.7)1.0 (ref)
No28 (66.7)14 (33.3)4.00 (0.65–24.55)
Lesion location p < 0.001
Others30 (73.2)11 (26.8)1.0 (ref)
Gingiva/palate0 (0.0)7 (100.0)1.64 (1.13–2.37)
Epithelial dysplasia p = 0.127
No/mild21 (72.4)8 (27.6)1.0 (ref)
Moderate/severe9 (47.4)10 (52.6)2.92 (0.87–9.82)
Figure 2

Kaplan–Meier curves for time to recurrence showed significance for lesion location (p < 0.001)

Univariable analysis of risk factor for recurrence OL after AFL‐PDT treatment Kaplan–Meier curves for time to recurrence showed significance for lesion location (p < 0.001)

Malignant transformation

During the 3‐year follow‐up period, the cumulative incidence of malignant transformation was 8.3% (4/48). Among them, CR and NR to AFL‐PDT was observed in two cases in each condition. The clinicopathological parameters of each patient with malignant transformation are presented in Table 2. Univariate analyses revealed that the severity of epithelial dysplasia (p = 0.02; OR: 2.93, 95% CI: 1.96–4.42) and recurrence (p = 0.016; OR: 3.14, 95% CI: 2.04–4.84) predisposed the patients to malignant transformation. No difference was observed in sex, location, and tobacco and alcohol history (p > 0.05). Clinical images of a representative patient with malignant transformation are shown in Figure 3.
Table 2

Clinicopathological parameters of patients with malignant transformation

SexAge (year)TobaccoAlcoholLocationEpithelial dysplasiaRecurrence time (month)Malignant transformation time (month)
1F67NoNoTongue, marginModerate1013
2F70NoNoGingivaModerate37
3M43YesYesTongue, marginModerate913
4F62NoNoTongue, marginSevere1415

Abbreviations: F, female; M, male.

Figure 3

Representative images for OL patients with malignant transformation. (A) A lesion on the tongue. (B) Most of the lesion disappeared with congestion at 1 month follow‐up. (C) The histopathology of the non‐homogenous lesion showed squamous cell carcinoma

Clinicopathological parameters of patients with malignant transformation Abbreviations: F, female; M, male. Representative images for OL patients with malignant transformation. (A) A lesion on the tongue. (B) Most of the lesion disappeared with congestion at 1 month follow‐up. (C) The histopathology of the non‐homogenous lesion showed squamous cell carcinoma

DISCUSSION

In a retrospective study evaluating PDT for OL, an overall response rate of 86.2% was achieved, including 55.2% CR and 31.0% PR, following 4.08 ± 1.73 PDT sessions. Other studies also reported a positive response of 72.3%–83.3% in patients who underwent 6–10 sessions of PDT. , The results of this study showed that 87.5% of the lesions responded to only one session of AFL‐PDT, which indicates that AFL can greatly improve the effectiveness of PDT treatment for OL, and AFL‐PDT shows excellent efficacy in OL treatment. The recurrence rates reported by two retrospective studies , that evaluated AFL for OL were 33.8% during an average 15‐month follow‐up and 32% in a >6‐month follow‐up. Studies , evaluating the effectiveness of PDT for OL have reported recurrence rates that ranged from 18.1% to 30.8% during 3–19 months follow‐up. Both recurrence rates in AFL and PDT for OL were higher than that in this study (37.5% recurrence during a 3‐year follow‐up). Compared with AFL and PDT, AFL‐PDT may be a more effective management strategy for OL treatment and reducing the risk of OL recurrence. In this study, each treatment area was limited to 4 cm2 or a diameter of 3 cm. When the lesion area exceeded the size limit, it was divided into multiple smaller areas for treatment. Each treatment area underwent one session of AFL‐PDT. This method may confirm the efficacy of AFL‐PDT. Intriguingly, lesions in the gingiva/palate (p < 0.001; OR: 1.64, 95% CI: 1.13–2.37) exhibited a higher risk of recurrence than that of other lesions. Alfonso et al. and Yuri et al. reported a consistent result, that the gingiva was the most common recurrence site. The gingiva/palate is subjected to friction and pressure when chewing. Furthermore, the mucosa of both sites was too thin to undergo operation with a sufficient safety margin, and consequently, gingiva and palate lesions were risk factors for recurrence. Interestingly, among the 18 enrolled lesions on the cheek mucosa in this study, 17 lesions responded to AFL‐PDT, and only three lesions recurred. None of the patients developed OSCC. These results suggest that compared to other sites, AFL‐PDT is particularly suitable for lesions on the cheek mucosa. A systematic review and meta‐analysis suggested that malignant transformation of OL is independent of laser treatment, including AFL, Nd: YAG laser, KTP laser, or diode laser. Based on the possibility of selective destruction of pathological tissues with accumulated photosensitizers, PDT has been successfully used in oncology. The malignant transformation rate of this study was 8.3%, which was comparable with the rates reported by other studies. , This study cannot yet evaluate the influence of AFL‐PDT on malignant transformation of OL because of the relatively small sample size and short follow‐up period. The severity of dysplasia was a common risk factor for malignant transformation, , which was also verified in this study (p = 0.02; OR: 2.93, 95% CI: 1.96–4.42). In the present study, 22.2% (4/18) of recurrent OLs transformed into OSCC, which was higher than that of non‐recurrent OLs (p = 0.016; OR: 3.14, 95% CI: 2.04–4.84). Three of four cases of malignant transformation were found in the margins of the tongue, which is recognized as a high‐risk site for OL malignant transformation. , Our findings should remind clinicians to arrange close follow‐up for OL recurrence, especially when lesions occur on the margin of the tongue. In the present study, OLs which showed CR to AFL‐PDT recurred and even transformed into OSCC. This suggests that clinicians should not take CR patients lightly, and close follow‐up is still required.

CONCLUSION

In conclusion, AFL‐PDT is an effective management of OL, but requires close follow‐up. OL lesions on the gingiva/palate are predisposed to recurrence. OLs that recur and those with moderate/severe epithelial dysplasia have a higher risk of malignant transformation. Randomised controlled studies with larger sample sizes and longer follow‐up times are needed to evaluate the influence of AFL‐PDT on OL malignant transformation.

CONFLICT OF INTERESTS

The authors declare are no conflict of interest.
  29 in total

1.  Photodynamic therapy in the treatment of oral leukoplakia: A systematic review.

Authors:  Yuting Li; Bingjie Wang; Saiwei Zheng; Yuan He
Journal:  Photodiagnosis Photodyn Ther       Date:  2018-11-01       Impact factor: 3.631

2.  European Dermatology Forum Guidelines on topical photodynamic therapy.

Authors:  Colin Morton; Rolf-Markus Szeimies; Alexis Sidoroff; Ann-Marie Wennberg; Nicole Basset-Seguin; Piergiacomo Calzavara-Pinton; Yolanda Gilaberte; Günther Hofbauer; Robert Hunger; Sigrid Karrer; Percy Lehmann; Stefano Piaserico; Claas Ulrich; Lasse Braathen
Journal:  Eur J Dermatol       Date:  2015 Jul-Aug       Impact factor: 3.328

Review 3.  Photodynamic therapy for skin cancer: How to enhance drug penetration?

Authors:  Mathilde Champeau; Séverine Vignoud; Laurent Mortier; Serge Mordon
Journal:  J Photochem Photobiol B       Date:  2019-07-02       Impact factor: 6.252

Review 4.  Interventions for treating oral leukoplakia to prevent oral cancer.

Authors:  Giovanni Lodi; Roberto Franchini; Saman Warnakulasuriya; Elena Maria Varoni; Andrea Sardella; Alexander R Kerr; Antonio Carrassi; L C I MacDonald; Helen V Worthington
Journal:  Cochrane Database Syst Rev       Date:  2016-07-29

Review 5.  Leukoplakia-A Diagnostic and Management Algorithm.

Authors:  Alessandro Villa; Sook Bin Woo
Journal:  J Oral Maxillofac Surg       Date:  2016-10-26       Impact factor: 1.895

6.  Ablative fractional laser-assisted photodynamic therapy vs. ablative fractional laser for oral leukoplakia treatment: A randomized, controlled pilot study.

Authors:  Yilin Yao; Linjun Shi; Yufeng Wang; Xuemin Shen; Sai Ye; Guoyao Tang; Lan Wu
Journal:  Photodiagnosis Photodyn Ther       Date:  2021-09-04       Impact factor: 3.631

7.  The treatment of oral leukoplakia with the CO2 laser: A retrospective study of 65 patients.

Authors:  Alfonso Mogedas-Vegara; Juan-Antonio Hueto-Madrid; Eduardo Chimenos-Küstner; Coro Bescós-Atín
Journal:  J Craniomaxillofac Surg       Date:  2015-03-26       Impact factor: 2.078

8.  Management of oral leukoplakia by laser surgery: relation between recurrence and malignant transformation and clinicopathological features.

Authors:  Junnosuke Ishii; Kunio Fujita; Sachiko Munemoto; Takahide Komori
Journal:  J Clin Laser Med Surg       Date:  2004-02

9.  Fractional laser-assisted delivery of methyl aminolevulinate: Impact of laser channel depth and incubation time.

Authors:  Christina S Haak; William A Farinelli; Joshua Tam; Apostolos G Doukas; R Rox Anderson; Merete Haedersdal
Journal:  Lasers Surg Med       Date:  2012-12-04       Impact factor: 4.025

Review 10.  Laser excision of oral leukoplakia: Does it affect recurrence and malignant transformation? A systematic review and meta-analysis.

Authors:  Mariana de Pauli Paglioni; Cesar Augusto Migliorati; Isabel Schausltz Pereira Faustino; Bruno Augusto Linhares Almeida Mariz; Ana Luiza Oliveira Corrêa Roza; Pablo Agustin Vargas; Adriana Franco Paes Leme; Thaís Bianca Brandão; Ana Carolina Prado Ribeiro; Marcio Ajudarte Lopes; Alan Roger Santos-Silva
Journal:  Oral Oncol       Date:  2020-06-12       Impact factor: 5.337

View more
  1 in total

1.  Management of oral leukoplakia by ablative fractional laser-assisted photodynamic therapy: A 3-year retrospective study of 48 patients.

Authors:  Yi-Lin Yao; Yu-Feng Wang; Chen-Xi Li; Lan Wu; Guo-Yao Tang
Journal:  Lasers Surg Med       Date:  2022-03-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.